Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10241 plus Almonertinib in MET-amplified NSCLC
NCT06110663Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dalmelitinib in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
dalmelitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06110663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06110663.